USMAN NASSIM 4
4 · GYRE THERAPEUTICS, INC. · Filed Apr 3, 2024
Insider Transaction Report
Form 4
USMAN NASSIM
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2024-04-01$6.93/sh+20,000$138,600→ 21,636 total - Sale
Common Stock
2024-04-01$16.15/sh−20,000$323,000→ 1,636 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-04-01−20,000→ 301,652 totalExercise: $6.93Exp: 2033-10-31→ Common Stock (20,000 underlying)
Holdings
- 77(indirect: By IRA)
Common Stock
- 563(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.80 to $17.15. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]This option is vested in full.